Strategic Focus Target early NAFLD diagnosis and monitoring customers by positioning TAEUS as a cost-effective liver fat quantification tool that enables point-of-care decisions, appealing to clinics and ambulatory imaging centers seeking alternatives to MRI or biopsy.

Biomarker Potential Leverage ENDRA’s biomarker direction for GLP-1 and metabolic disease therapies to engage pharma and contract research organizations interested in non-invasive monitoring tools that can complement GLP-1 treatment regimens and MASH programs.

Regulatory Path Highlight de novo submission progress and FDA discussions as a credential for safety and efficacy, guiding sales conversations with hospital systems and integrated delivery networks that seek validated innovations with regulatory credibility.

Partnership Opportunities Propose collaborations with large imaging players, contract developers, and payer pilots by underscoring existing strategic funding activity and potential to accelerate market access through co-development, distributions, or funded trials.

Financial Cadence Acknowledge smaller company funding stage and recent capital raises to tailor flexible pricing, capex-light deployments, and scalable service models that align with budget cycles of mid-market clinics, specialty centers, and academic hospitals.